Follicular lymphoma pathophysiology: Difference between revisions
Jump to navigation
Jump to search
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AS}} | {{CMG}}; {{AE}} {{AS}} | ||
==Overview== | ==Overview== | ||
Genes involved in the pathogenesis of follicular lymphoma include ''[[BCL-2]]'' and ''BCL-6''. The progression to follicular lymphoma involves [[microRNAs]] (miRNAs). On microscopic histopathological analysis, centrocytes and | Genes involved in the pathogenesis of follicular lymphoma include ''[[BCL-2]]'' and ''[[BCL-6 corepressor|BCL-6]]''. The most common cause is reciprocal [[Chromosomal translocation|translocation]] t(14;18)(q32;q21). The progression to follicular lymphoma involves [[microRNAs]] (miRNAs). On microscopic histopathological analysis, centrocytes, centroblasts along with various non-neoplastic cells including [[T cell|T cells]], [[follicular dendritic cells]], and [[Macrophage|macrophages]] are characteristic findings of follicular lymphoma. | ||
==Pathophysiology== | ==Pathophysiology== | ||
=== Physiology === | === Physiology === | ||
* Follicular helper T cells (Tfh) are specialized helper T cells that are predominantly located in germinal centers | * Follicular [[T helper cell|helper T]] cells (Tfh) are specialized helper T cells that are predominantly located in germinal centers alongwith B cells. | ||
* Follicular lymphoma is the second most common non-Hodgkin lymphoma. | * Follicular lymphoma is the second most common [[non-Hodgkin lymphoma]]. | ||
* The disease is characterized by the clonal proliferation of neoplastic lymphoid cells that share morphological, immunophenotypic and molecular genetic attributes of germinal centre B cells. | * The disease is characterized by the clonal proliferation of neoplastic lymphoid cells that share morphological, immunophenotypic and molecular genetic attributes of germinal centre B cells. | ||
* The development of | * The development of follicular lymphoma tumors in adults is dependent upon the overexpression of B cell leukemia/lymphoma 2 ([[Bcl-2|BCL-2)]] located on chromosome band 18q21. | ||
* BCL-2 is an oncogene that blocks programmed cell death (apoptosis). As such, overexpression results in prolonged cell survival. | * BCL-2 is an [[oncogene]] that blocks programmed cell death ([[apoptosis]]). As such, overexpression results in prolonged cell survival. | ||
* These tumours contain a mixture of neoplastic centrocytes and centroblasts along with various non-neoplastic cells including T cells, follicular dendritic cells, and macrophages. | * These tumours contain a mixture of [[Cancer|neoplastic]] centrocytes and centroblasts along with various non-neoplastic cells including T cells, follicular dendritic cells, and macrophages. | ||
* | * Follicular lymphoma can be designated as low grade (1 and 2) or higher grade (3A and 3B) disease, depending on the number of centroblasts per high-power field. | ||
===Pathogenisis=== | ===Pathogenisis.=== | ||
* The most common cause is reciprocal [[Chromosomal translocation|translocation]] between (14;18)(q32;q21) in 80-85% of cases. | |||
* The most common cause is reciprocal translocation | |||
* This somatic rearrangement | * This somatic rearrangement is initiated within the bone marrow during B-cell [[lymphopoiesis]] and results from [[Antibody|immunoglobulin]] heavy chain gene (''IGH'') rearrangement. | ||
* The t(14;18) translocation leads to placement of the B cell lymphoma 2 (''BCL2'') gene under the | * The t(14;18) translocation leads to placement of the B cell lymphoma 2 (''BCL2'') gene under the influence of [[Transcriptional regulation|transcriptional]] enhancers associated with ''IGH'', resulting in overexpression of anti-apoptotic ''BCL2'' leading to increased cell survival and uncontrolled cell proliferation in germinal centres. | ||
* BCL2, along with other anti-apoptotic proteins, inhibits apoptosis by binding and neutralizing activated pro-apoptotic proteins including the mitochondrial outer membrane permeabilizers BAX and BAK, as well as the intracellular stress sensors | * BCL2, along with other anti-[[Apoptosis|apoptotic]] proteins, inhibits apoptosis by binding and neutralizing activated pro-apoptotic proteins including the [[Mitochondrion|mitochondrial]] outer membrane permeabilizers [[Bcl-2-associated X protein|BAX]] and [[BAK1|BAK]], as well as the intracellular stress sensors which activate BAX and BAK. | ||
* Mutations in chromatin-modifying genes occur, affecting histone methyltransferases, histone acetyltransferases or histone linker proteins. | * Mutations in chromatin-modifying genes occur, affecting histone methyltransferases, histone acetyltransferases or histone linker proteins. | ||
* These mutations act to promote | * These mutations act to promote increased proliferation of [[B cell|B cells]]. | ||
* Genes encoding components of vacuolar H+-ATPase, or RRAGC, a guanine nucleotide binding protein, regulate mTOR activation. | * Genes encoding components of vacuolar H+-ATPase, or RRAGC, a guanine nucleotide binding protein, regulate the mTOR activation. | ||
* Mutations in these genes upregulate mTOR (mammalian target of rapamycin) signaling in FL cells. These mutations are found in approximately 15 to 20 percent of cases. | * [[Mutation|Mutations]] in these genes upregulate [[Mammalian target of rapamycin|mTOR]] (mammalian target of rapamycin) signaling in FL cells. These mutations are found in approximately 15 to 20 percent of cases. | ||
* Upregulated mTOR directs many cellular processes including growth, differentiation, survival, and adhesion or cellular migration, and resulting in follicular lymphoma development. | * Upregulated mTOR directs many cellular processes including growth, differentiation, survival, and adhesion or cellular migration, and resulting in follicular lymphoma development. | ||
* KMT2D, CREBBP, EZH2, EP300, HIST1H1E, KMT2C, ARID1A, and SMARCA4 are some of the other genomes which undergo mutations in a very few cases. | * KMT2D, CREBBP, EZH2, EP300, HIST1H1E, KMT2C, ARID1A, and SMARCA4 are some of the other genomes which undergo mutations in a very few cases. | ||
* The tumor | * The tumor microenvironment comprised of T cells and [[Dendritic cell|dendritic]] cells, may influence the development and progression of Follicular lymphoma. | ||
* Communication between the tumor cells and the microenvironment involves chemokines, chemokine receptors and adhesion molecules, the balance of which determines whether there is tumor cell growth promotion or inhibition. | * Communication between the tumor cells and the microenvironment involves [[Chemokine|chemokines]], chemokine receptors and adhesion molecules, the balance of which determines whether there is tumor cell growth promotion or inhibition. | ||
* MicroRNA expression- short non-coding RNAs named [[microRNAs]] (miRNAs) have important functions in follicular lymphoma biology. | * MicroRNA expression- short non-coding RNAs named [[microRNAs]] (miRNAs) have important functions in follicular lymphoma biology. | ||
* In malignant B cells miRNAs participate in pathways fundamental to B cell development like | * In malignant B cells miRNAs participate in pathways fundamental to B cell development like: | ||
** B cell receptor (BCR) signalling | |||
**B cell receptor (BCR) signalling | ** B cell migration/adhesion, cell-cell interactions in immune complexes. | ||
**B cell migration/adhesion, cell-cell interactions in immune | |||
**The production and class-switching of [[immunoglobulins]].<ref name="pmid25541152">{{Cite journal | pmid = 25541152| year = 2014| author1 = Musilova| first1 = K| title = MicroRNAs in B cell lymphomas: How a complex biology gets more complex| journal = Leukemia| last2 = Mraz| first2 = M| doi = 10.1038/leu.2014.351}}</ref> | **The production and class-switching of [[immunoglobulins]].<ref name="pmid25541152">{{Cite journal | pmid = 25541152| year = 2014| author1 = Musilova| first1 = K| title = MicroRNAs in B cell lymphomas: How a complex biology gets more complex| journal = Leukemia| last2 = Mraz| first2 = M| doi = 10.1038/leu.2014.351}}</ref> | ||
* MiRNAs influence B cell maturation, generation of pre marginal zone, follicular, B1, plasma and memory B cells<ref name="pmid25541152" /> | * MiRNAs influence B cell maturation, generation of pre marginal zone, follicular, B1, plasma and memory B cells<ref name="pmid25541152" /> | ||
* It is positive for the B-cell markers [[CD10]], [[CD19]], [[CD22]], and usually [[CD20]],<ref>[http://pleiad.umdnj.edu/hemepath/follicular/follicular.html Overview] at [[University of Medicine and Dentistry of New Jersey|UMDNJ]]</ref> | * It is positive for the B-cell markers [[CD10]], [[CD19]], [[CD22]], and usually [[CD20]],<ref>[http://pleiad.umdnj.edu/hemepath/follicular/follicular.html Overview] at [[University of Medicine and Dentistry of New Jersey|UMDNJ]]</ref> . | ||
===Genetics=== | ===Genetics=== | ||
Revision as of 20:43, 27 December 2018
|
Follicular lymphoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Follicular lymphoma pathophysiology On the Web |
|
American Roentgen Ray Society Images of Follicular lymphoma pathophysiology |
|
Risk calculators and risk factors for Follicular lymphoma pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
Genes involved in the pathogenesis of follicular lymphoma include BCL-2 and BCL-6. The most common cause is reciprocal translocation t(14;18)(q32;q21). The progression to follicular lymphoma involves microRNAs (miRNAs). On microscopic histopathological analysis, centrocytes, centroblasts along with various non-neoplastic cells including T cells, follicular dendritic cells, and macrophages are characteristic findings of follicular lymphoma.
Pathophysiology
Physiology
- Follicular helper T cells (Tfh) are specialized helper T cells that are predominantly located in germinal centers alongwith B cells.
- Follicular lymphoma is the second most common non-Hodgkin lymphoma.
- The disease is characterized by the clonal proliferation of neoplastic lymphoid cells that share morphological, immunophenotypic and molecular genetic attributes of germinal centre B cells.
- The development of follicular lymphoma tumors in adults is dependent upon the overexpression of B cell leukemia/lymphoma 2 (BCL-2) located on chromosome band 18q21.
- BCL-2 is an oncogene that blocks programmed cell death (apoptosis). As such, overexpression results in prolonged cell survival.
- These tumours contain a mixture of neoplastic centrocytes and centroblasts along with various non-neoplastic cells including T cells, follicular dendritic cells, and macrophages.
- Follicular lymphoma can be designated as low grade (1 and 2) or higher grade (3A and 3B) disease, depending on the number of centroblasts per high-power field.
Pathogenisis.
- The most common cause is reciprocal translocation between (14;18)(q32;q21) in 80-85% of cases.
- This somatic rearrangement is initiated within the bone marrow during B-cell lymphopoiesis and results from immunoglobulin heavy chain gene (IGH) rearrangement.
- The t(14;18) translocation leads to placement of the B cell lymphoma 2 (BCL2) gene under the influence of transcriptional enhancers associated with IGH, resulting in overexpression of anti-apoptotic BCL2 leading to increased cell survival and uncontrolled cell proliferation in germinal centres.
- BCL2, along with other anti-apoptotic proteins, inhibits apoptosis by binding and neutralizing activated pro-apoptotic proteins including the mitochondrial outer membrane permeabilizers BAX and BAK, as well as the intracellular stress sensors which activate BAX and BAK.
- Mutations in chromatin-modifying genes occur, affecting histone methyltransferases, histone acetyltransferases or histone linker proteins.
- These mutations act to promote increased proliferation of B cells.
- Genes encoding components of vacuolar H+-ATPase, or RRAGC, a guanine nucleotide binding protein, regulate the mTOR activation.
- Mutations in these genes upregulate mTOR (mammalian target of rapamycin) signaling in FL cells. These mutations are found in approximately 15 to 20 percent of cases.
- Upregulated mTOR directs many cellular processes including growth, differentiation, survival, and adhesion or cellular migration, and resulting in follicular lymphoma development.
- KMT2D, CREBBP, EZH2, EP300, HIST1H1E, KMT2C, ARID1A, and SMARCA4 are some of the other genomes which undergo mutations in a very few cases.
- The tumor microenvironment comprised of T cells and dendritic cells, may influence the development and progression of Follicular lymphoma.
- Communication between the tumor cells and the microenvironment involves chemokines, chemokine receptors and adhesion molecules, the balance of which determines whether there is tumor cell growth promotion or inhibition.
- MicroRNA expression- short non-coding RNAs named microRNAs (miRNAs) have important functions in follicular lymphoma biology.
- In malignant B cells miRNAs participate in pathways fundamental to B cell development like:
- B cell receptor (BCR) signalling
- B cell migration/adhesion, cell-cell interactions in immune complexes.
- The production and class-switching of immunoglobulins.[1]
- MiRNAs influence B cell maturation, generation of pre marginal zone, follicular, B1, plasma and memory B cells[1]
- It is positive for the B-cell markers CD10, CD19, CD22, and usually CD20,[2] .
Genetics
- A translocation between chromosome 14 and 18 results in the overexpression of the BCL-2 gene.[3]
- The BCL-2 gene is normally found on chromosome 18, and the translocation moves the gene near to the site of the immunoglobulin heavy chain enhancer element on chromosome 14.
- Translocations of BCL6 at 3q27 can also be involved.[4]
Gross Pathology
-
Classic appearance of spleen involved by follicular lymphoma, namely the presence of discrete, miliary, small, white "pearly" nodules throughout the whole parenchyma.
-
Follicular lymphoma replacing a lymph node.
Microscopic Pathology
The tumor is composed of follicles containing a mixture of the following:
- Centrocytes (small cleaved cells without nucleoli)
- Centroblasts (larger noncleaved cells with moderate cytoplasm, open chromatin and multiple nucleoli)
- These follicles are surrounded by non-malignant cells, mostly T-cells.
Within the follicles, centrocytes typically predominate; centroblasts are usually scarce.
-
Micrograph of a follicular lymphoma, showing the characteristically abnormal lymphoid follicles. H&E stain
Grading
According to the WHO criteria, the disease is morphologically graded into:[5]
- grade 1 (<5 centroblasts per high-power field (hpf))
- grade 2 (6–15 centroblasts/hpf)
- grade 3 (>15 centroblasts/hpf)
- grade 3A (centrocytes still present)
- grade 3B (the follicles consist almost entirely of centroblasts)
The WHO 2008 update provided the following grading for follicular lymphoma:
- Grades 1 and 2 now as low grade follicular lymphoma
- Grade 3A as high grade follicular lymphoma
- Grade 3B as diffuse large B Cell lymphoma
References
- ↑ 1.0 1.1 Musilova, K; Mraz, M (2014). "MicroRNAs in B cell lymphomas: How a complex biology gets more complex". Leukemia. doi:10.1038/leu.2014.351. PMID 25541152.
- ↑ Overview at UMDNJ
- ↑ Bosga-Bouwer AG, van Imhoff GW, Boonstra R; et al. (February 2003). "Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive". Blood. 101 (3): 1149–54. doi:10.1182/blood.V101.3.1149. PMID 12529293.
- ↑ Bosga-Bouwer AG, Haralambieva E, Booman M; et al. (November 2005). "BCL6 alternative translocation breakpoint cluster region associated with follicular lymphoma grade 3B". Genes Chromosomes Cancer. 44 (3): 301–4. doi:10.1002/gcc.20246. PMID 16075463.
- ↑ "Follicular Lymphomas". Retrieved 2008-07-26.